International medical cannabis revenue increased by 36%, while Canadian adult-use cannabis revenue grew by 6%. Tilray Pharma achieved record quarterly revenue. U.S. federal cannabis rescheduling is expected to open new market opportunities for Tilray’s medical expansion into the U.S. The company reported a strong financial position with $292 million in cash and securities and approximately $30 million in net cash.

Tilray reported a record second fiscal quarter with net revenue reaching $218 million. The company’s diversified portfolio in cannabis, beverage, wellness, and distribution sectors contributed to a 3% increase in net revenue. Tilray sees federal rescheduling in the U.S. as a key opportunity for medical cannabis advancement, aiming to leverage its experience for future growth.

Financial highlights for Tilray’s second quarter include a 3% increase in net revenue to $217.5 million compared to the previous year. Gross profit was $57.5 million with a gross margin of 26%. Cannabis net revenue increased by 3%, with international cannabis up 36% and Canadian adult-use cannabis up 6%. Beverage net revenue decreased to $50.1 million.

Cash flow for Tilray improved, with cash used in operations decreasing to $(8.5) million. The balance sheet showed growth in cash and marketable securities to $291.6 million and a reduction in total outstanding debt by $4.2 million. The net cash position improved to $27.4 million.

Adjusted EBITDA outlook for fiscal 2026 is reaffirmed at $62 million – $72 million. Tilray will host a webcast to discuss these results, available on their investor relations website. The company aims to be a leading premium lifestyle company with a focus on cannabis, beverage, wellness, and entertainment.

Read more at GlobeNewswire: Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of